On Oct 28, major Wall Street analysts update their ratings for $HCA Healthcare (HCA.US)$, with price targets ranging from $396 to $460.
Morgan Stanley analyst Craig Hettenbach maintains with a hold rating, and adjusts the target price from $427 to $406.
Barclays analyst Andrew Mok CFA maintains with a buy rating, and maintains the target price at $396.
TD Cowen analyst Ryan Langston maintains with a buy rating, and adjusts the target price from $450 to $440.
RBC Capital analyst Ben Hendrix maintains with a buy rating, and maintains the target price at $405.
Truist Financial analyst David S Macdonald maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $HCA Healthcare (HCA.US)$'s main analysts recently are as follows:
The performance of HCA Healthcare was anticipated to encounter disruptions due to hurricanes. A 'bigger surprise', however, was the projection for EBITDA and EPS in 2025, which fell below market expectations and ended a streak of strong financial outperformances. Despite the allure of the stock's recent 9% decline, there is a belief that it may enter a phase of consolidation.
HCA Healthcare's third-quarter results demonstrated resilience, overcoming the negative impacts of hurricanes, which are anticipated to persist into the fourth quarter and push full-year 2024 guidance towards the lower end. Despite these ongoing challenges, the company's management anticipates earnings growth in 2025 to meet or exceed its long-term objectives, supported by an admissions growth forecast of 3%-4%, which is considered above the usual trend.
The firm revised its model after evaluating HCA Healthcare's third-quarter results. Despite high anticipations for the quarter, the company delivered a robust underlying performance, evidenced by a 7.1% increase in same-store revenues compared to the previous year's third-quarter comparison of 7.9%.
HCA Healthcare's Q3 results aligned with market expectations, influenced by solid same-store volumes and increased Medicaid DPPs, which balanced out the interruptions caused by hurricanes. Following the earnings announcement, the company's stock experienced a significant drop, which is thought to be a result of projected EBITDA for 2025 slightly trailing market estimates, a market shift in anticipation of the upcoming election, and a perception of high valuation.
Here are the latest investment ratings and price targets for $HCA Healthcare (HCA.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月28日，多家华尔街大行更新了$HCA医疗 (HCA.US)$的评级，目标价介于396美元至460美元。
摩根士丹利分析师Craig Hettenbach维持持有评级，并将目标价从427美元下调至406美元。
巴克莱银行分析师Andrew Mok CFA维持买入评级，维持目标价396美元。
TD Cowen分析师Ryan Langston维持买入评级，并将目标价从450美元下调至440美元。
加皇资本市场分析师Ben Hendrix维持买入评级，维持目标价405美元。
储亿银行分析师David S Macdonald维持买入评级。
此外，综合报道，$HCA医疗 (HCA.US)$近期主要分析师观点如下：
hca医疗的表现预计会因飓风遭遇中断。然而，2025年EBITDA和每股收益的预测却出乎意料地低于市场预期，终结了一系列强劲的财务表现。尽管该股最近下跌了9%，但有人认为它可能进入一段整固期。
hca医疗的第三季度业绩表现出色，克服了飓风的负面影响，预计负面影响将持续到第四季度，并将2024年全年指引拉向较低端。尽管面临持续挑战，公司管理层预计2025年收入增长将达到或超过长期目标，得益于3%-4%的入院增长预测，这被认为高于通常趋势。
该公司在评估了hca医疗第三季度的业绩后进行了模型修订。尽管对本季度寄予厚望，但公司交出了强劲的基本业绩，同店销售收入相比去年同期增长了7.1%，而去年同期的增长率为7.9%。
hca医疗的第三季度业绩符合市场预期，受到实体店同店销售量的稳固支撑以及医疗补助计划（Medicaid DPPs）增加的影响，平衡了飓风造成的中断。在盈利公告后，该公司股票经历了大幅下跌，这被认为是2025年EBITDA略低于市场预期、市场在预期即将到来的选举而发生转变、以及高估值感知的结果。
以下为今日6位分析师对$HCA医疗 (HCA.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
